Precision Therapeutics’ subsidiary TumorGenesis and its partner 48Hour Discovery Inc. receive Alberta Innovates Product Demonstration Program grant to support development of novel cancer treatments

April 16, 2019 | | Uncategorized |

Collaboration receives $300,000 CAD grant to further develop and commercialize TumorGenesis oncology discovery technologies MINNEAPOLIS, April 16, 2019 (GLOBE NEWSWIRE) – Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its wholly owned subsidiary, TumorGenesis, is participating with 48Hour Discovery (48HD),...

Read More